A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1
Recruiting
- Conditions
- HER2 Mutation-Related TumorsHER2HER2-positive Breast CancerHER2 + Breast CancerBrain Metastases from Solid TumorsBrain Metastases from HER2 and Breast CancerCNS MetastasesHER2-Positive Solid TumorsNSCLC (non-small Cell Lung Cancer)HER2-positive Bladder Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Iambic Therapeutics, Inc
- Target Recruit Count
- 243
- Registration Number
- NCT06253871
- Locations
- 🇺🇸
Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath